{
    "clinical_study": {
        "@rank": "63862", 
        "arm_group": [
            {
                "arm_group_label": "Proflavine followed by high resolution microscopic imaging", 
                "arm_group_type": "Experimental", 
                "description": "5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa.  The HRME will then be inserted through the endoscope and gently placed against the mucosa.  Imaging of abnormal tissues will be performed."
            }, 
            {
                "arm_group_label": "Standard of care", 
                "arm_group_type": "No Intervention", 
                "description": "No invention"
            }
        ], 
        "brief_summary": {
            "textblock": "The overall objective of this multicenter trial is to determine whether the use of a\n      low-cost, high-resolution microendoscope during diagnostic upper endoscopy can improve the\n      efficiency and accuracy of endoscopic screening for esophageal squamous cell neoplasia.\n      This is a multicenter clinical trial of a novel technology, a miniaturized, lower cost (<\n      $3, 500) microscope device which can be used during upper endoscopy to image the\n      gastrointestinal epithelium.  This high-resolution microendoscope  (HRME) was developed by\n      our collaborators at RICE University and provides >1000X magnified images of the esophageal\n      mucosa."
        }, 
        "brief_title": "High Resolution Microendoscopy for the Detection of Esophageal Squamous Cell Neoplasia", 
        "completion_date": {
            "#text": "December 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Suspected or Known Squamous Cell Neoplasia", 
            "Prior History of Squamous Cell Dysplasia and /or Neoplasia"
        ], 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Known or suspected squamous cell cancer\n\n          -  History of squamous cell dysplasia\n\n          -  History of squamous cell cancer\n\n          -  18 years or older\n\n        Exclusion Criteria:\n\n          -  Subjects unfit for standard upper endoscopy\n\n          -  Allergy or prior reaction to the fluorescent contrast agent proflavine\n\n          -  Known advanced squamous cell carcinoma of the distal esophagus, or\n             dysplastic/suspected malignant esophageal lesion > 2 cm in size not amenable to\n             endoscopic therapy\n\n          -  Patients unable to undergo routine endoscopy with biopsy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1800", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02029937", 
            "org_study_id": "GCO 13-0396"
        }, 
        "intervention": {
            "arm_group_label": "Proflavine followed by high resolution microscopic imaging", 
            "description": "5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa.  The HRME will then be inserted through the endoscope and gently placed against the mucosa.  Imaging of abnormal tissues will be performed.", 
            "intervention_name": "Proflavine hemisulfate follwed by high resolution microscopic imaging", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Proflavine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "squamous cell neoplasia", 
            "Proflavine", 
            "Lugol's chromoendoscopy"
        ], 
        "lastchanged_date": "January 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10029"
                }, 
                "name": "Icahn School of Medicine at Mount Sinai"
            }, 
            "investigator": {
                "last_name": "Sharmila Anandasabapathy, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "High Resolution Microendoscopy for the Detection of Esophageal Squamous Cell Neoplasia: A Randomized, Multicenter Trial of Accuracy, Yield, and Clinical Impact", 
        "other_outcome": {
            "measure": "Comparison of the performance characteristics of HRME to LC for the  prediction of squamous esophageal neoplasia using histopatholgy as the gold standard. The cost-effectiveness of HRME-LC to LC alone.", 
            "safety_issue": "No", 
            "time_frame": "1 day"
        }, 
        "overall_contact": {
            "email": "josephine.mitcham@mountsinai.org", 
            "last_name": "Josephine Mitcham, BA", 
            "phone": "212-824-7837"
        }, 
        "overall_official": {
            "affiliation": "Mount Sinai School of Medicine", 
            "last_name": "Sharmila Anandasabapathy, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Efficiency described as:\nDiagnostic yield: The number of neoplastic biopsies/total number of biopsies obtained in patients who received biopsies.\n'Patient saved': # of patients who received no biopsies\nProcedure time:  Total procedure time in the HRME-LC arm compared to the LC arm.", 
            "measure": "Comparison of the efficiency of HRME+Lugol's chromoendoscopy (HRME+LC) to that of Lugol's chromoendoscopy alone (LC) for the diagnosis of esophageal squamous cell neoplasia.", 
            "safety_issue": "No", 
            "time_frame": "1 day"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02029937"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Determination whether HRME changes the decision to perform endoscopic therapy or perform a mucosal biopsy", 
            "safety_issue": "No", 
            "time_frame": "1 day"
        }, 
        "source": "Anandasabapathy, Sharmila, M.D.", 
        "sponsors": {
            "collaborator": {
                "agency": "William Marsh Rice University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Anandasabapathy, Sharmila, M.D.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}